Pumpkin seed oil (Cucurbita pepo) versus tamsulosin for benign prostatic hyperplasia symptom relief: a single-blind randomized clinical trial.


Journal

BMC urology
ISSN: 1471-2490
Titre abrégé: BMC Urol
Pays: England
ID NLM: 100968571

Informations de publication

Date de publication:
19 Oct 2021
Historique:
received: 02 06 2021
accepted: 06 10 2021
entrez: 20 10 2021
pubmed: 21 10 2021
medline: 28 1 2022
Statut: epublish

Résumé

Benign prostatic hyperplasia (BPH) is very common in aging men. We aimed to compare the effects of tamsulosin and pumpkin (Cucurbita pepo) seed oil on BPH symptoms. This single-blind randomized clinical trial included patients with BPH aged ≥ 50 years referred to the Urology Clinic of Shahid Beheshti Hospital, Hamadan, Iran, from August 23, 2019 to February 19, 2020. Patients were randomized into two groups. One group received 0.4 mg tamsulosin every night at bedtime and the other received 360 mg pumpkin seed oil twice a day. Patients' age, weight, height, and body mass index (BMI) were recorded. The International Prostate Symptom Score (IPSS) was filled out by the patients at baseline and then 1 month and 3 months after the initiation of treatment. The BPH-associated quality of life (QoL), serum prostate-specific antigen, prostate and postvoid residual volume, and maximum urine flow were also assessed at baseline and 3 months later. Drug side effects were also noted. Of the 73 patients included in this study with a mean age of 63.59 ± 7.04 years, 34 were in the tamsulosin group and 39 in the pupkin seed oil group. Patients were comparable with respect to age, weight, height, BMI, and baseline principal variables in both groups. Also, there was no significant difference between groups in terms of principal variables at any time point. However, there was a significant decrease in IPSS and a significant improvement in QoL in both groups. Although the decrease in IPSS from baseline to 1 month and 3 months was significantly higher in the tamsulosin group compared to the pumpkin group (P = 0.048 and P = 0.020, respectively), the decrease in IPSS from 1 to 3 months was similar (P = 0.728). None of the patients in the pumpkin group experienced drug side effects, while dizziness (5.9%), headache (2.9%), retrograde ejaculation (2.9%), and erythema with pruritus occurred in the tamsulosin group. Pumpkin (Cucurbita pepo) seed oil relieved BPH symptoms with no side effects, but was not as effective as tamsulosin. Further studies are required to confirm the role of pumpkin seed oil as an option for the treatment of BPH symptoms. Trial registration Iranian Registry of Clinical Trials, IRCT20120215009014N340. Registered 19.02.2020. Retrospectively registered, https://en.irct.ir/trial/45335 .

Sections du résumé

BACKGROUND BACKGROUND
Benign prostatic hyperplasia (BPH) is very common in aging men. We aimed to compare the effects of tamsulosin and pumpkin (Cucurbita pepo) seed oil on BPH symptoms.
METHODS METHODS
This single-blind randomized clinical trial included patients with BPH aged ≥ 50 years referred to the Urology Clinic of Shahid Beheshti Hospital, Hamadan, Iran, from August 23, 2019 to February 19, 2020. Patients were randomized into two groups. One group received 0.4 mg tamsulosin every night at bedtime and the other received 360 mg pumpkin seed oil twice a day. Patients' age, weight, height, and body mass index (BMI) were recorded. The International Prostate Symptom Score (IPSS) was filled out by the patients at baseline and then 1 month and 3 months after the initiation of treatment. The BPH-associated quality of life (QoL), serum prostate-specific antigen, prostate and postvoid residual volume, and maximum urine flow were also assessed at baseline and 3 months later. Drug side effects were also noted.
RESULTS RESULTS
Of the 73 patients included in this study with a mean age of 63.59 ± 7.04 years, 34 were in the tamsulosin group and 39 in the pupkin seed oil group. Patients were comparable with respect to age, weight, height, BMI, and baseline principal variables in both groups. Also, there was no significant difference between groups in terms of principal variables at any time point. However, there was a significant decrease in IPSS and a significant improvement in QoL in both groups. Although the decrease in IPSS from baseline to 1 month and 3 months was significantly higher in the tamsulosin group compared to the pumpkin group (P = 0.048 and P = 0.020, respectively), the decrease in IPSS from 1 to 3 months was similar (P = 0.728). None of the patients in the pumpkin group experienced drug side effects, while dizziness (5.9%), headache (2.9%), retrograde ejaculation (2.9%), and erythema with pruritus occurred in the tamsulosin group.
CONCLUSIONS CONCLUSIONS
Pumpkin (Cucurbita pepo) seed oil relieved BPH symptoms with no side effects, but was not as effective as tamsulosin. Further studies are required to confirm the role of pumpkin seed oil as an option for the treatment of BPH symptoms. Trial registration Iranian Registry of Clinical Trials, IRCT20120215009014N340. Registered 19.02.2020. Retrospectively registered, https://en.irct.ir/trial/45335 .

Identifiants

pubmed: 34666728
doi: 10.1186/s12894-021-00910-8
pii: 10.1186/s12894-021-00910-8
pmc: PMC8527717
doi:

Substances chimiques

Plant Oils 0
Urological Agents 0
KLK3 protein, human EC 3.4.21.-
Kallikreins EC 3.4.21.-
Prostate-Specific Antigen EC 3.4.21.77
Tamsulosin G3P28OML5I

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

147

Subventions

Organisme : Hamadan University of Medical Sciences
ID : IR.UMSHA.REC.1398.429
Organisme : Hamadan University of Medical Sciences
ID : IR.UMSHA.REC.1398.429

Informations de copyright

© 2021. The Author(s).

Références

BMC Urol. 2019 Mar 11;19(1):17
pubmed: 30871552
Chin Med J (Engl). 2011 Jan;124(1):56-60
pubmed: 21362308
J Urol. 2011 May;185(5):1793-803
pubmed: 21420124
Planta Med. 2006 Jul;72(9):807-13
pubmed: 16783690
Urol Int. 2015;94(3):286-95
pubmed: 25196580
Eur Urol. 2007 Oct;52(4):964-72
pubmed: 17618043
J Med Food. 2006 Summer;9(2):284-6
pubmed: 16822218
Pharmacol Res. 1995 Jan;31(1):73-9
pubmed: 7784309
J West Afr Coll Surg. 2016 Oct-Dec;6(4):1-30
pubmed: 29181363
Fitoterapia. 2016 Apr;110:150-6
pubmed: 26976217
Urol Int. 2006;77(3):269-74
pubmed: 17033217
Am J Clin Exp Urol. 2018 Apr 01;6(2):62-77
pubmed: 29666834
Nutr Res Pract. 2009 Winter;3(4):323-7
pubmed: 20098586
Sci Rep. 2017 Aug 11;7(1):7984
pubmed: 28801563
Forsch Komplementarmed Klass Naturheilkd. 2000 Aug;7(4):200-4
pubmed: 11025395
BJU Int. 2007 Oct;100(4):820-5
pubmed: 17550412
Can Urol Assoc J. 2018 Oct;12(10):303-312
pubmed: 30332601
Urol Clin North Am. 2009 Nov;36(4):403-15, v
pubmed: 19942041
Consult Pharm. 2016;31(8):412-24
pubmed: 27535076
J Pak Med Assoc. 2014 Jun;64(6):683-5
pubmed: 25252490
Can Urol Assoc J. 2017 Oct;11(10):298-309
pubmed: 29381452
Urol Clin North Am. 2016 Aug;43(3):289-97
pubmed: 27476122

Auteurs

Nikan Zerafatjou (N)

Department of Urology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. nikan.zerafatjou@gmail.com.

Mohammadali Amirzargar (M)

Urology and Nephrology Research Center, Hamadan University of Medical Sciences, Hamadan, Iran.

Mahdi Biglarkhani (M)

Department of Persian Medicine, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.

Farzaneh Shobeirian (F)

Department of Radiology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.

Ghazal Zoghi (G)

Endocrinology and Metabolism Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH